The Medical Advisor

Nicolas Hulscher and colleagues conducted a survey of 197 Cancer patients taking Ivermectin and Mebendazole for 6 months (abstract below) and confirmed: 84.4% reported a clinical benefit  32.8% reported No evidence of disease  15.6% reported tumor regression The study began with 197 cancer patients, and 122 completed follow-up. Patients were prescribed capsules containing 25 mg ivermectin and 250 mg mebendazole. They took up to 4 capsules per day according to physician’s recommendation. Self-reported cancer outcomes at 6-month follow-up (N=122) Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort (2026) Abstract Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. ...

Abstract Background: Stage 4 cancer — defined by metastatic spread beyond the original tumor site — has a poor prognosis with conventional treatment alone. There is growing interest in repurposed antiparasitic drugs such as ivermectin , fenbendazole , and mebendazole for potential antineoplastic effects. Preclinical research suggests mechanisms including disruption of oncogenic signaling pathways and inhibition of cancer cell proliferation and survival, but controlled clinical evidence in humans remains limited. Objective: To summarize and characterize a large compilation of anecdotal clinical case reports describing the use of ivermectin, fenbendazole, and mebendazole in individuals with Stage 4 cancers (various tumor types) and to highlight reported outcomes and therapeutic contexts. Methods: Over 320 individual case reports were aggregated from public sources — predominantly social media posts, practitioner-shared testimonials, and independently published patient narratives....